Pathogens & Immunity
Overview
Pathogens & Immunity is a scientific journal, published since 2016 in English. The journal's country of origin is United States.
Details
Details
Abbr.
Pathog Immun
Start
2016
End
Continuing
Frequency
Quarterly, 2017-
e-ISSN
2469-2964
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 12197
21
SJR / Ranks: 2140
1422
CiteScore / Ranks: 1928
8.70
Recent Articles
11.
Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, et al.
Pathog Immun
. 2024 Oct;
10(1):1-11.
PMID: 39391808
Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel...
12.
Greenspan N
Pathog Immun
. 2024 Oct;
9(2):94-134.
PMID: 39381058
In this interview, Jonathan Yewdell talks with senior editor Neil Green-span about the evolution of viral immunology, highlighting his work and the contributions of other influential scientists. He emphasizes the...
13.
Juste M, Joseph Y, Lespinasse D, Apollon A, Jamshidi P, Lee M, et al.
Pathog Immun
. 2024 Sep;
9(2):172-193.
PMID: 39345793
Background: A primary barrier to curing HIV is the HIV reservoir. The leading infectious cause of death worldwide for people living with HIV is tuberculosis (TB), but we do not...
14.
Hausman B, Memic S, Cadnum J, Zink E, Wilson B, Donskey C
Pathog Immun
. 2024 Sep;
9(2):194-204.
PMID: 39345792
Background: The potential for promotion of intestinal colonization with healthcare-associated pathogens by new antibiotics used to treat infections due to multidrug-resistant Gram-negative bacilli is unclear. Methods: Mice treated for 3...
15.
Lederman M, Greenspan N
Pathog Immun
. 2024 Sep;
9(2):152-171.
PMID: 39315014
No abstract available.
16.
Paul M, Choudhary M, Heaps A, Deo R, Moisi D, Gordon K, et al.
Pathog Immun
. 2024 Sep;
9(2):79-93.
PMID: 39247686
Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an anti-viral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses...
17.
Gierke A, Hessling M
Pathog Immun
. 2024 Sep;
9(2):135-151.
PMID: 39247685
Background: The World Health Organization has published a list of pathogenic fungi with prior-itizing groups and calls for research and development of antifungal measures, with belonging to the group with...
18.
Parikh U, Heaps A, Moisi D, Gordon K, Mellors J, Choudhary M, et al.
Pathog Immun
. 2024 Aug;
9(2):58-78.
PMID: 39165724
Background: Assessing the breadth and duration of antigen-specific binding antibodies provides valuable information for evaluating interventions to treat or prevent SARS-CoV-2 infection. Multiplex immunoassays are a convenient method for rapid...
19.
Sherman K, Rouster S, Meeds H, Peters M, Blackard J, Horn P, et al.
Pathog Immun
. 2024 Aug;
9(2):43-57.
PMID: 39135958
Background: Newer biomarkers of Hepatitis B virus (HBV) infection and treatment response have not been well-characterized in individuals with HBV/HIV coinfection. Methods: Pre-genomic RNA (pgRNA) and quantitative HBsAg (qHBsAg) were...
20.
Zielinski N, Baiceanu D, Dragomir A, Heyckendorf J, Ibraim E, Kohler N, et al.
Pathog Immun
. 2024 Jun;
9(2):25-42.
PMID: 38939039
Background: Neuropathic adverse events occur frequently in linezolid-containing regimens, some of which remain irreversible after drug discontinuation. Objective: We aimed to identify and validate a host RNA-based biomarker that can...